Whats the deal with TDM-105795?
    Research/Science 3/11/2026

    At a glance
    In this research discussion post, the primary subjects mentioned are the tone is 😐 neutral with potential for enhanced growth results.

    Other terms

    TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.
    View this post in the Community →

    Similar Community Posts Join

    5 / 40 results

      community TDM-105795 phase 2 results are in!

      in Research/Science  28 upvotes 2 years ago
      TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

      community Is there any new drug that looks promising ?

      in Research/Science  26 upvotes 2 years ago
      The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  133 upvotes 2 years ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

    Related Research

    6 / 36 results